Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19174385 | 0.81 | MGAM (0.41) | ALDH1A1HSD17B10L3MBTL1HPGD | |
| SCHEMBL10771721 | 0.81 | SMN1; SMN2 (0.43) | TSHRALDH1A1SMN1; SMN2RAB9AKDM4E | |
| SCHEMBL19174264 | 0.80 | — | — | |
| SCHEMBL19174522 | 0.79 | SMN1; SMN2 (0.39) | TSHRALDH1A1SMN1; SMN2RAB9AKDM4E | |
| SCHEMBL17215175 | 0.78 | TSHR (0.43) | TSHRALDH1A1SMN1; SMN2RAB9AKDM4E | |
| SCHEMBL7429232 | 0.78 | TSHR (0.39) | TSHRALDH1A1SMN1; SMN2RAB9AKDM4E | |
| SCHEMBL19174358 | 0.77 | TSHR (0.37) | TSHR | |
| SCHEMBL807266 | 0.76 | TSHR (0.45) | TSHRALDH1A1SMN1; SMN2RAB9AKDM4E | |
| SCHEMBL18726371 | 0.76 | TSHR (0.45) | TSHRALDH1A1SMN1; SMN2RAB9AKDM4E | |
| SCHEMBL17011289 | 0.74 | TSHR (0.44) | TSHRALDH1A1SMN1; SMN2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190315785-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20170210770-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315785-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | PIK3CA, TYMP, ITPA | TSHR 4872/4885ALDH1A1 4577/4885SMN1; SMN2 4228/4885 |
| US-20170210770-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | PIK3CA, TYMP, ITPA | TSHR 4872/4885ALDH1A1 4577/4885SMN1; SMN2 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.